➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Merck
Boehringer Ingelheim
AstraZeneca
McKesson

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PENTAZOCINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Pentazocine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00125931 ↗ Effects of Pentazocine on Manic Symptoms Completed Stanley Medical Research Institute Phase 2 2005-09-01 The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments.
NCT00125931 ↗ Effects of Pentazocine on Manic Symptoms Completed Mclean Hospital Phase 2 2005-09-01 The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments.
NCT00431184 ↗ Effects of Pentazocine Versus Lorazepam on Manic Symptoms Completed Stanley Medical Research Institute Phase 2 2007-01-01 Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.
NCT00431184 ↗ Effects of Pentazocine Versus Lorazepam on Manic Symptoms Completed Mclean Hospital Phase 2 2007-01-01 Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study. We will examine whether pentazocine, an agent with kappa-opiate activity, decreases manic symptoms.
NCT00499746 ↗ The Discriminative Effects of Tramadol in Humans Completed National Institute on Drug Abuse (NIDA) Phase 1/Phase 2 2007-11-01 This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.
NCT01315158 ↗ Propofol vs Propofol + Benzo/Opiates in High Risk Group Terminated Washington University School of Medicine N/A 2011-01-01 This will be a randomized controlled trial that compares the rates of sedation related complications in high risk patients (ASA greater or equal to 3, BMI greater or equal to 30, those at risk for OSA) undergoing advanced endoscopy procedures with propofol alone compared to propofol in combination with benzodiazepines and opioids.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pentazocine Hydrochloride

Condition Name

Condition Name for Pentazocine Hydrochloride
Intervention Trials
Bipolar Disorder 2
Anesthesia 1
Manic State 1
Pleurisy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pentazocine Hydrochloride
Intervention Trials
Bipolar Disorder 2
Disease 1
Empyema 1
Hot Flashes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pentazocine Hydrochloride

Trials by Country

Trials by Country for Pentazocine Hydrochloride
Location Trials
United States 4
Nigeria 1
India 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pentazocine Hydrochloride
Location Trials
Washington 1
Missouri 1
Maryland 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pentazocine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Pentazocine Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pentazocine Hydrochloride
Clinical Trial Phase Trials
Completed 5
Unknown status 1
Enrolling by invitation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pentazocine Hydrochloride

Sponsor Name

Sponsor Name for Pentazocine Hydrochloride
Sponsor Trials
Mclean Hospital 2
Stanley Medical Research Institute 2
National Center for Complementary and Integrative Health (NCCIH) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pentazocine Hydrochloride
Sponsor Trials
Other 11
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
AstraZeneca
McKesson
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.